Floodlight App Gets Positive Ratings, Shows Good Continuous Use in Pilot Study

Floodlight App Gets Positive Ratings, Shows Good Continuous Use in Pilot Study

Publication date: Sep 05, 2019

This post was originally published on this site Using smartphones and smartwatches to monitor disease course via the FLOODLIGHT app leads to high adherence and satisfaction among patients with multiple sclerosis (MS), results from a pilot study show. The research, -Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study,” was published in the Journal of Medical Internet Research. The test battery included active tests performed daily, weekly, every two weeks, or on demand for 24 weeks, and passive monitoring, which analyzed sensor-based gait and mobility. Adherence to both active tests and passive monitoring for the 24 weeks was good, and remained stable over time after week six. Data showed that 70% of participants completed all active tests, 75% did all active tests except the 2MWT, and 79% had data collected via smartphone- or smartwatch-based passive monitoring. FLOODLIGHT tests are being assessed in long-term studies with larger patient groups in the CONSONANCE Phase 3b trial of Ocrevus (ocrelizumab, by Roche-owned Genentech) in people with progressive MS (NCT03523858; still enrolling, contact information is here), and in a global study open to all MS patients with a mobile device, called FLOODLIGHT Open. The post Floodlight App Gets Positive Ratings, Shows Good Continuous Use in Pilot Study appeared first on Multiple Sclerosis News Today.

Concepts Keywords
Barcelona Mobile device
Battery Smartphones
California Magnetic resonance imaging
Clinical Trials Android
Cognitive Impairment Adherence
Floodlight Smartwatch
Gait Wearable computers
Genentech Smartphones
Magnetic Resonance Imaging Wearable devices
Mobile Device Cloud clients
Multiple Sclerosis Digital technology
Progressive Mobile computers
Questionnaire Operating systems
San Francisco Computing
Sensor MS
Smartphone Larger patient groups
Smartphones Studyopen mobile device
Smartwatch Magnetic resonance imaging
Symptom
Test

Semantics

Type Source Name
disease MESH cognitive impairment
disease MESH gait
disease MESH posture
drug DRUGBANK Tropicamide
disease DOID multiple sclerosis
disease MESH multiple sclerosis
gene UNIPROT SLC35G1
disease MESH satisfaction
gene UNIPROT DESI1
gene UNIPROT APP
gene UNIPROT EGR3
gene UNIPROT IMPACT
disease DOID relapsing-remitting MS
gene UNIPROT ANP32B
gene UNIPROT TNFSF13
drug DRUGBANK Ocrelizumab
drug DRUGBANK Nonoxynol-9

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *